Jazz Pharmaceuticals plc is a global biopharmaceutical firm dedicated to discovering, advancing, and bringing to market innovative medicines for conditions where treatment options are lacking, serving patients across the United States, Europe, and other international regions.
Jazz Pharmaceuticals stock last closed at $230.56, down 2.38% from the previous day, and has increased 109.04% in one year. It has overperformed other stocks in the Biotechnology industry by 1.82 percentage points. Jazz Pharmaceuticals stock is currently +119.58% from its 52-week low of $105.00, and -5.24% from its 52-week high of $243.32.
There are currently 62.74M JAZZ shares outstanding. The market capitalization of JAZZ is $14.47B. In the last 24 hours, 629,000 JAZZ shares were traded.
You will need an online brokerage account in order to access the NASDAQ market and buy JAZZ stock.
Based on our research, eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've selected your brokerage, it's time to fill out some personal info so you can invest in JAZZ stock today.
Now that you've created your account on our top ranked stock app, you can securely and quickly fund your account:
Check out the tutorial below if you need help depositing money into your new brokerage account.
Once you have decided on the best place to buy Jazz Pharmaceuticals stock, it's important to analyze their stock before you invest, so you can wrap your head around the risk and upside.
WallStreetZen was designed to help average investors do more accurate fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on JAZZ's stock page.
Investors use many financial metrics, analyses, models, and charts to gauge JAZZ's true value.
Using relative valuations ratios:
You can do additional valuation analysis on JAZZ's stock here.
Out of 12 Equities analysts who track JAZZ, the consensus analyst rating on JAZZ is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they investment advice.
Joseph Thome, a bottom 16% analyst from TD Cowen maintains JAZZ with a strong buy rating and raises their JAZZ price target from $220.00 to $275.00, on May 6, 2026.
TD Cowen's Joseph Thome raised their price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) by 25% from $220 to $275 on 2026/05/06. The analyst maintained their Strong Buy rating on the stock.
Jazz Pharmaceuticals reported its Q1 2026 earnings.
Raising their price target, Thome headlined that large Xywav and Zepzelca's beats drove the quarter's sales ($1.069B) well past the $983MM consensus.
The analyst noted that management remains optimistic about the company's marketed products' long-term growth trajectory.
For Q1 2026, Jazz Pharmaceuticals reported:
For FY 2026, management guided:
President & CEO Renee Gala commented: "Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026.
"Demand for Xywav remained strong, our rare oncology launches with Modeyso™ and Zepzelca® in 1LM ES-SCLC gained significant momentum, and Epidiolex continued to provide consistent growth.
"Looking ahead, we are excited about the potential launch of zanidatamab in 1L GEA later this year, as we progress our pipeline and business development efforts to bring more life-changing therapies to patients and fuel durable long-term growth."
Leonid Timashev, a top 7% analyst from RBC Capital maintains JAZZ with a buy rating and raises their JAZZ price target from $195.00 to $258.00, on May 6, 2026.
Mohit Bansal, a top 14% analyst from Wells Fargo maintains JAZZ with a strong buy rating and raises their JAZZ price target from $250.00 to $265.00, on May 6, 2026.
Marc Goodman, a top 9% analyst from Leerink Partners maintains JAZZ with a buy rating and raises their JAZZ price target from $215.00 to $225.00, on Apr 22, 2026.
Jeffrey Hung, a top 8% analyst from Morgan Stanley maintains JAZZ with a strong buy rating and raises their JAZZ price target from $225.00 to $226.00, on Feb 25, 2026.
You can dig deeper into what analysts are saying on the Jazz Pharmaceuticals stock forecast page.
Last year, JAZZ earnings were $29.49M. In the last five year, JAZZ's earnings have gone up by -44.94% per year. This was slower than the Biotechnology industry average of 12.7%.
Last year, JAZZ revenue was $4.44B. In the last 5 year, JAZZ's revenue has grown by 12.75% per year. This was slower than the Biotechnology industry average of 32.07%.
Find out more about JAZZ's earnings and revenue performance here.
In the last 12 months, executives and large shareholders at JAZZ have sold more shares than they have bought.
Neena M. Patil, EVP Chief Legal Officer of JAZZ, was the latest JAZZ insider to sell. They sold $278,196.00 worth of JAZZ stock on Jun 10, 2026.
Learn more about who owns JAZZ shares here.
No, Jazz Pharmaceuticals doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
You have two main types of orders:
Press the Open button and your broker will execute the order.
If you require more help with investing in stocks on eToro, click the how to video below:
Now that you own some shares in JAZZ, you'll want to keep up with your investment.
Make a watchlist to track your JAZZ stock.
To reiterate, here are the 6 steps to buy Jazz Pharmaceuticals stock:
If you are looking for a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest news on your investment in Jazz Pharmaceuticals, add JAZZ to your watchlist by clicking the button below.